• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D filed by NRX Pharmaceuticals Inc.

    9/13/22 4:47:33 PM ET
    $NRXP
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $NRXP alert in real time by email
    SC 13D 1 form13d.htm

     

     

     

    UNITED STATES 

    SECURITIES AND EXCHANGE COMMISSION 

    Washington, D.C. 20549

     

    SCHEDULE 13D

     

    Under the Securities Exchange Act of 1934 

    (Amendment No. ________)*

     

    NRX Pharmaceuticals, Inc.

     

    (Name of Issuer)

     

    Common Stock, par value $0.001 per share

     

    (Title of Class of Securities)

     

    629444 100

     

    (CUSIP Number)

     

    Daniel C. Javitt

    c/o Glytech, LLC

    800 Park Avenue, Suite 1803 

    Fort Lee, NJ 07024

    13473912793

     

    (Name, Address and Telephone Number of Person 

    Authorized to Receive Notices and Communications)

     

    July 1, 2022

     

    (Date of Event which Requires Filing of this Statement)

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ☐

     

    Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent.

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     
     

     

    CUSIP No. 629444 100 13D Page 2 of 6 Pages

     

       
    1.

    NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    Daniel C. Javitt

    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP 

    (see instructions) 

    (a)     ☐ 

    (b)     ☐

    3.

    SEC USE ONLY 

     

    4.

    SOURCE OF FUNDS (see instructions) 

     

    OO

    5.

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)     ☐

     

    6.

    CITIZENSHIP OR PLACE OF ORGANIZATION 

     

    USA

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    7.

    SOLE VOTING POWER

     

    0

    8.

    SHARED VOTING POWER

     

    9,872,901

    9.

    SOLE DISPOSITIVE POWER

     

    9,872,901

    10.

    SHARED DISPOSITIVE POWER

     

    0

    11.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 

     

    9,872,901

    12.

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES 

    (see instructions)    ☐ 

     

    13.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

    14.6%

    14.

    TYPE OF REPORTING PERSON (see instructions) 

     

    IN

     

     
     

     

    CUSIP No. 629444 100 13D Page 3 of 6 Pages

     

    The following constitutes the Schedule 13D filed by the undersigned (the “Schedule 13D”). This Schedule 13D (including all amendments hereto) is intended to satisfy the undersigned’s continued reporting obligations since the filing by the undersigned of Amendment No. 1 to the joint Schedule 13D, dated November 2, 2021 (the “Previous Schedule 13D”), which included the undersigned as a Reporting Person. 

     

    Item 1. Security and Issuer.

     

    This statement on Schedule 13D relates to the shares of common stock, $0.001 par value per share (the “Common Stock”), of NRX Pharmaceuticals, Inc., a Delaware Corporation (the “Issuer”) whose principal executive office is located at 1201 Orange Street, Suite 600, Wilmington, Delaware 19801. 

     

    Item 2. Identity and Background.

     

    (a) This statement is filed by the sole owner and member of Glytech, LLC, Daniel C. Javitt (“Reporting Person”), with respect to the Shares beneficially owned by him.

     

    The Reporting Person is party to that certain Voting Agreement (as referenced in Item 4) with Jonathan C. Javitt (“Dr. J. Javitt”). As a result, the Reporting Person may be deemed to be a member of a “group,” within the meaning of Section 13(d)(3) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), comprised of the Reporting Person and Dr. J. Javitt. The Reporting Person previously jointly filed the Previous Schedule 13D with Dr. J. Javitt, however the Reporting Person is filing this Schedule 13D individually pursuant to Rule 13d-1(k)(2) of the Exchange Act. It is the understanding of the Reporting Person that Dr. J. Javitt has filed a separate Schedule 13D, including an amendment thereto, with respect to his ownership of Shares pursuant to Rule 13d-1(k)(2) of the Exchange Act. Reference is made to such Schedule 13D as amended for information concerning Dr. J. Javitt and his investment in the Issuer. The Reporting Person expressly disclaims beneficial ownership of any securities beneficially owned or directly held by any other person.

     

    (b) The principal business address of the Reporting Person is c/o Glytech LLC, 800 Park Avenue, Suite 1803, Fort Lee, NJ 07024.

     

    (c) The principal occupation of the Reporting Person is sole member, Glytech LLC and Professor of Psychiatry, Columbia University Irving College of Medicine, New York, NY 10032

     

    (d) The Reporting Person has not, during the past five years (or ever), been convicted in a criminal proceeding, traffic violation or similar misdemeanors.

     

    (e) The Reporting Person has not, during the past five years (or ever), been party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

     

    (f) The Reporting Person is a citizen of the United States of America.

     

    Item 3. Source or Amount of Funds or Other Consideration.

     

    The shares of Common Stock held indirectly by the Reporting Person were received in connection with the merger described in that certain Agreement and Plan of Merger, dated as of December 13, 2020 (the “Merger”), by and among Big Rock Partners Acquisition Corp. (“BRPA”), Big Rock Merger Corp., a Delaware corporation and wholly owned subsidiary of BRPA, and NeuroRx, Inc. (the “Predecessor Company”), through an exchange of shares held in the Predecessor Company. On the effective date of the Merger, the closing price of the Common Stock was $24.25 per share. 

     

     
     

     

    CUSIP No. 629444 100 13D Page 4 of 6 Pages

     

    Item 4. Purpose of Transaction.

     

    Reference is made to the Registration Rights Agreement, the Lock-Up Agreement, the Voting Agreement, the Private Placement and the Private Placement Lock-Up Agreements, each as defined and further described in Item 4 of the Previous Schedule 13D and incorporated herein by reference. 

     

    On May 31, 2022, the Issuer became eligible to register the sale of its securities on Form S-3 under the Securities Act and Glytech, of which the Reporting Person is sole owner, exercised its right to require the Issuer to register for resale all of the shares of Common Stock held by Glytech (all of which are beneficially owned by the Reporting Person) pursuant to the Registration Rights Agreement, as was anticipated at the time of the business combination with BRPA. On June 10, 2022, a post-effective amendment on Form S-3 to Form S-1 that registered for resale all of the shares of Common Stock held by Glytech was declared effective by the SEC.

     

    The information set forth in Item 6 regarding the 2022 Sales Plan is incorporated herein by reference. Other than the 2022 Sales Plan, the Reporting Person does not have any present plan or proposal which would relate to or result in any of the matters set forth in subparagraphs (a) - (j) of Item 4 of Schedule 13D except as set forth herein or such as would occur upon or in connection with completion of, or following, any of the actions discussed herein. Depending on various factors including, without limitation, the Issuer’s financial position and investment strategy, the price levels of the Common Stock, conditions in the securities markets and general economic and industry conditions, the Reporting Person may in the future take such actions with respect to his investment in the Issuer as he deems appropriate including, without limitation, engaging in additional communications with management and the Board of the Issuer, engaging in discussions with stockholders of the Issuer or third parties, including potential acquirers and service providers about the Issuer and the Reporting Person’s investment, entering into a 10b-5 sales plan, making proposals to the Issuer concerning changes to the capital allocation strategy, capitalization, ownership structure, including a sale of the Issuer as a whole or in parts, Board structure (including Board composition) or operations of the Issuer, or purchasing additional Common Stock, selling some or all of the Common Stock beneficially owned by him, engaging in short selling of or any hedging or similar transaction with respect to the Common Stock, each subject to the Issuer’s securities trading policy, or changing his intention with respect to any and all matters referred to in this Item 4.

     

    Glytech, LLC is an early-stage pharmaceutical company focused on developing novel treatments for serious and persistent mental disorders, and holds multiple patents in the area of schizophrenia, depression and PTSD. Funds generated by the 2022 Sales Plan will be used in part to support ongoing operations of Glytech, LLC and expansion of the existing patent portfolio.

     

    Item 5. Interest in Securities of the Issuer.

     

    The aggregate percentage of shares of Common Stock reported owned by the Reporting Person is based upon 67,641,314 shares outstanding as of August 12, 2022, which is the total number of shares of Common Stock outstanding as of that date as reported in the Issuer’s Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission on August 15, 2022.

     

    (a) As of the date hereof, the Reporting Person beneficially owns 9,872,901 shares of Common Stock directly held by Glytech LLC, a Delaware limited liability company (“Glytech”) solely owned by the Reporting Person, which represents approximately 14.6% of the outstanding Common Stock. The Reporting Person maintains shared voting and sole investment power over such shares.

     

    Based on public filings, the Reporting Person believes that Dr. J. Javitt beneficially owns 14,868,329 shares of Common Stock consisting of (i) 13,299,997 shares of Common Stock held by the Jonathan Javitt Living Trust, (ii) 1,422,000 shares of Common Stock held by The Javitt 2012 Irrevocable Dynasty Trust, and (iii) 146,332 shares of Common Stock held by Dr. J. Javitt individually. Collectively, the Reporting Person and Dr. J. Javitt beneficially own 24,741,230 shares of Common Stock, which represents approximately 36.6% of the outstanding Common Stock. The Reporting Person disclaims beneficial ownership of the shares that he does not directly own. Furthermore, the Reporting Person expressly disclaims beneficial ownership of the 14,868,329 shares of Common Stock beneficially owned by Dr. J. Javitt.

     

    (b)1. Sole power to vote or direct vote: 0 shares
    2. Shared power to vote or direct vote: 9,872,901 shares
    3. Sole power to dispose or direct the disposition: 9,872,901 shares
    4. Shared power to dispose or direct the disposition: 0 shares

     

    (c) The transactions involving shares of Common Stock beneficially owned by the Reporting Person since the filing of the Previous Schedule 13D are set forth in Schedule A and are incorporated herein by reference. The information set forth in Item 6 regarding the 2022 Sales Plan is incorporated herein by reference.

     

    (d) No person other than the Reporting Person is known to have the right to receive, or the power to direct the receipt of dividends from, or proceeds from the sale of, the shares of Common Stock beneficially owned by him.

     

    (e) Not applicable.

     

     
     

     

    CUSIP No. 629444 100 13D Page 5 of 6 Pages

     

    Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer.

     

    Effective June 13, 2022, Glytech entered into a Sales Plan (the “2022 Sales Plan”) with J.P. Morgan Securities LLC (“JPMS”) for the purpose of establishing a trading plan to effect sales of shares of Common Stock in compliance with all applicable laws, including, without limitation, Section 10(b) of the Exchange Act, and the rules and regulations promulgated thereunder, including, but not limited to, Rule 10b5-1. The 2022 Sales Plan was entered into during the Issuer’s open trading window in accordance with the Reporting Person’s status as an affiliate, as determined by his beneficial ownership of greater than 10% of the outstanding shares of Common Stock.

     

    Shares of Common Stock sold pursuant to the 2022 Sales Plan may only be sold in accordance with trading parameters adopted by Glytech in the 2022 Sales Plan, and there can be no assurance as to how many shares of Common Stock will be sold pursuant to the 2022 Sales Plan or at what price any such shares of Common Stock will be sold, subject to the applicable trading parameters. On July 29, 2022, an aggregate of 784,063 shares of Common Stock were sold in open market transactions on the Nasdaq Stock Market pursuant to the 2022 Sales Plan at an average sales price of $1.0094 per share.

     

    Reference is made to the Registration Rights Agreement, the Lock-Up Agreement, the Voting Agreement, the Private Placement and the Private Placement Lock-Up Agreements, as referenced in Item 4 above. Other than as set forth herein, there are no contracts, arrangements, understandings or relationships between the Reporting Person and any other person with respect to the securities of the Issuer.

     

    Item 7. Material to Be Filed as Exhibits.

     

    Ex. 99.1 Registration Rights Agreement (incorporated by reference to Exhibit 10.8 to the Issuer’s current report on Form 8-K filed by the Issuer on May 28, 2021). 
     
    Ex. 99.2 Lock-up Agreement, dated May 24, 2021, by and between BRPA and the stockholder parties identified therein (incorporated by reference to Exhibit 10.7 to the Issuer’s current report on Form 8-K filed by the Issuer on May 28, 2021). 
     
    Ex. 99.3 Voting Agreement, dated May 24, 2021, by and between Jonathan Javitt and the Reporting Person (incorporated by reference to Exhibit 10.34 to the Issuer’s current report on Form 8-K filed by the Issuer on May 28, 2021).
     
    Ex. 99.4  Securities Purchase Agreement, dated August 19, 2021, by and among NRX Pharmaceuticals, Inc. and certain purchasers named on the signature pages thereto (incorporated by reference to Exhibit 10.1 to the Issuer’s current report on Form 8-K filed by the Issuer on August 24, 2021). 
     
    Ex. 99.5  Lock-up Agreement, dated August 19, 2021, by and among Jonathan Javitt, the Reporting Person and NRX Pharmaceuticals, Inc. (incorporated by reference to Exhibit 10.4 to the Issuer’s current report on Form 8-K filed by the Issuer on August 24, 2021).

     

     
     

     

    CUSIP No. 629444 100 13D Page 6 of 6 Pages

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

      /s/ Daniel C. Javitt
      Daniel C. Javitt
       
      September 13, 2022
      Date 

     

     
     

     

    SCHEDULE A

     

    Date  Transaction  Number of Shares of Common Stock  Price Per Share
              
    6/3/22  Open market sales   243,596   $0.7024 
                  
    6/6/22  Open market sales   115,657   $0.6653 
                  
    6/7/22  Open market sales   86,459   $0.6461 
                  
    7/1/22  Gift to CRUT   2,000,000    N/A 
                  
    7/29/22  Open market sales under 2022 Sales Plan   784,063   $1.0094 

     

     

     

    Get the next $NRXP alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $NRXP

    DatePrice TargetRatingAnalyst
    4/2/2025$18.00Buy
    BTIG Research
    More analyst ratings

    $NRXP
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D filed by NRX Pharmaceuticals Inc.

      SC 13D - NRX Pharmaceuticals, Inc. (0001719406) (Subject)

      9/13/22 4:47:33 PM ET
      $NRXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by NRX Pharmaceuticals Inc. (Amendment)

      SC 13D/A - NRX Pharmaceuticals, Inc. (0001719406) (Subject)

      6/17/22 5:00:47 PM ET
      $NRXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D filed by NRX Pharmaceuticals Inc.

      SC 13D - NRX Pharmaceuticals, Inc. (0001719406) (Subject)

      6/3/22 3:59:15 PM ET
      $NRXP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NRXP
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • BTIG Research initiated coverage on NRx Pharmaceuticals with a new price target

      BTIG Research initiated coverage of NRx Pharmaceuticals with a rating of Buy and set a new price target of $18.00

      4/2/25 8:51:11 AM ET
      $NRXP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NRXP
    SEC Filings

    See more
    • NRX Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - NRX Pharmaceuticals, Inc. (0001719406) (Filer)

      5/21/25 4:38:02 PM ET
      $NRXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SCHEDULE 13G filed by NRX Pharmaceuticals Inc.

      SCHEDULE 13G - NRX Pharmaceuticals, Inc. (0001719406) (Subject)

      5/15/25 5:15:19 PM ET
      $NRXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by NRX Pharmaceuticals Inc.

      10-Q - NRX Pharmaceuticals, Inc. (0001719406) (Filer)

      5/15/25 5:01:16 PM ET
      $NRXP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NRXP
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Chief Financial Officer Abrams Michael S

      4 - NRX Pharmaceuticals, Inc. (0001719406) (Issuer)

      2/11/25 5:00:05 PM ET
      $NRXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chairman and Chief Scientist Javitt Jonathan C bought $46,800 worth of shares (40,000 units at $1.17), increasing direct ownership by 90% to 84,634 units (SEC Form 4)

      4 - NRX Pharmaceuticals, Inc. (0001719406) (Issuer)

      12/18/24 8:27:36 AM ET
      $NRXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3 filed by new insider Abrams Michael S

      3 - NRX Pharmaceuticals, Inc. (0001719406) (Issuer)

      11/22/24 1:44:01 PM ET
      $NRXP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NRXP
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chairman and Chief Scientist Javitt Jonathan C bought $46,800 worth of shares (40,000 units at $1.17), increasing direct ownership by 90% to 84,634 units (SEC Form 4)

      4 - NRX Pharmaceuticals, Inc. (0001719406) (Issuer)

      12/18/24 8:27:36 AM ET
      $NRXP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NRXP
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $NRXP
    Leadership Updates

    Live Leadership Updates

    See more
    • NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) and HOPE Therapeutics™, Inc. Selected to Present at the Wall Street Conference on May 21, 2025, in Palm Beach, Florida

      PALM BEACH, Fla., May 21, 2025 /PRNewswire/ -- NRx Pharmaceuticals, Inc. ("NRx" or the "Company") (NASDAQ:NRXP), a clinical-stage biopharmaceutical company, today announced that that Jonathan Javitt, MD, MPH, Founder, Chairman and Chief Executive Officer of NRx Pharmaceuticals and Co-CEO of HOPE Therapeutics, will be presenting a Company update at the upcoming Wall Street Conference, taking place on May 21, 2025 in Palm Beach, FL. NRx is one of six companies invited to present. The Wall Street Conference is expected to host over 1,000 attendees who are reported to represent ov

      5/21/25 8:03:00 AM ET
      $NRXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Reports First Quarter 2025 Financial Results and Provides Corporate Update

      Company has continued to advance its previously announced plan to obtain FDA approval for two new drugs and to develop a network of clinics focused on neuroplastic therapies to treat severe and suicidal depression, PTSD, and related conditions. Clinic acquisition financing is at the HOPE Therapeutics level and non-dilutive to NRXP shareholdersIn January 2025 completed the third tranche of a convertible note offering and registered direct equity offering to an institutional investor on favorable terms to the Company; expected to provide sufficient cash to support operations through the end of 2025. Deployed capital to meet the objectives listed belowNRX-100 (preservative-free IV ketamine) pla

      5/15/25 4:03:00 PM ET
      $NRXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HOPE Therapeutics, Inc. a subsidiary of NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announces Signing of Term Sheet for $7.8 Million Debt Financing to Fuel HOPE Clinic Acquisitions

      Term sheet with Universal Capital, LLC to fund HOPE Therapeutics clinic acquisition strategyFunding tied to already-announced acquisitions, with additional tranches contemplated for further growth, subject to standard due diligenceTogether with previously announced term sheet with a strategic investor, HOPE funding of $10.3 million is planned in the near term MIAMI, May 15, 2025 /PRNewswire/ -- HOPE Therapeutics™, Inc. ("HOPE"), a multi-site clinical care delivery organization and wholly-owned subsidiary of NRx Pharmaceuticals, Inc. (NASDAQ:NRXP), a clinical-stage biopharmaceutical company, today announced signing of a term sheet with Universal Capital, LLC ("Universal") to provide $7.8 mill

      5/15/25 10:15:00 AM ET
      $NRXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HOPE Therapeutics, Inc. and NRx Pharmaceuticals (NASDAQ:NRXP) Announce Signing of Definitive Agreement to Purchase Kadima Neuropsychiatry Institute; Foundational Acquisition for the HOPE Network of Interventional Psychiatry Clinics

      Kadima Neuropsychiatry Institute in La Jolla, CA expected to serve as clinical model for Hope treatment offerings nationwideKadima is a leading investigative site for CNS and psychedelic research, having served as the lead site in nearly all major trials in this spaceDr. David Feifel, a nationally recognized pioneer in interventional psychiatry to join HOPE as Chief Medical Innovation Officer upon closing Acquisition expected to be accretive to revenue and EBITDA for NRx and HOPEMIAMI, May 13, 2025 /PRNewswire/ -- HOPE Therapeutics™, Inc. ("HOPE"), a medical and technology-driven company and wholly-owned subsidiary of NRx Pharmaceuticals, Inc. ("NRx" or the "Company") (NASDAQ:NRXP), a clinic

      5/13/25 8:03:00 AM ET
      $NRXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announces the Appointment of Michael Taylor to its Board of Directors and Appointment of Anita Nunes as Board Observer; Ms. Nunes to be Appointed Director of HOPE Therapeutics, Inc.

      WILMINGTON, Del., Jan. 15, 2025 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, and HOPE Therapeutics, Inc., a development stage medical and technology driven company and wholly owned subsidiary of NRx, today announced the appointment of Mr. Michael Taylor and Ms. Anita Nunes as Member and Observer of its Board of Directors, respectively.  Ms. Nunes is also to be appointed to the Board of Directors of Hope Therapeutics, Inc. Michael Taylor brings over 25 years of experience in global cr

      1/15/25 8:02:00 AM ET
      $NRXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HOPE Therapeutics™, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Alert Investors to Sanjay Gupta/CNN Program on Ketamine, Featuring Kadima Neuropsychiatry Institute Founder Dr. David Feifel

      "'Special K': The Science & Stigma of Ketamine" on CNN, hosted by Dr. Sanjay GuptaDavid Feifel MD PHD, Founder of Kadima, is a global thought leader in the interventional psychiatry fieldKadima Neuropsychiatry Institute identified as planned HOPE Flagship Clinic pending acquisition closingDr. Feifel is expected to join HOPE as Chief Medical Innovation OfficerMIAMI, Jan. 14, 2025 /PRNewswire/ -- HOPE Therapeutics™, Inc., ("HOPE"), a medical and technology driven company, and a wholly-owned subsidiary of NRx Pharmaceuticals, Inc. ("NRx", and collectively with HOPE, the "Company") (NASDAQ:NRXP), today alerted investors that Kadima Neuropsychiatry Institute's Founder David Feifel, MD PHD was fea

      1/14/25 8:03:00 AM ET
      $NRXP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NRXP
    Financials

    Live finance-specific insights

    See more
    • NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Reports First Quarter 2025 Financial Results and Provides Corporate Update

      Company has continued to advance its previously announced plan to obtain FDA approval for two new drugs and to develop a network of clinics focused on neuroplastic therapies to treat severe and suicidal depression, PTSD, and related conditions. Clinic acquisition financing is at the HOPE Therapeutics level and non-dilutive to NRXP shareholdersIn January 2025 completed the third tranche of a convertible note offering and registered direct equity offering to an institutional investor on favorable terms to the Company; expected to provide sufficient cash to support operations through the end of 2025. Deployed capital to meet the objectives listed belowNRX-100 (preservative-free IV ketamine) pla

      5/15/25 4:03:00 PM ET
      $NRXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) to Report First Quarter 2025 Financial Results on May 15, 2025

      WILMINGTON, Del., May 12, 2025 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that it will release its first quarter 2025 financial results after the market closes on Thursday, May 15, 2025 via press release, which will be available on the Company's website at https://ir.nrxpharma.com/. The Company will host a conference call to discuss the financial results as well as provide a corporate update at 4:30pm ET the same day. A live webcast of the conference call will be av

      5/12/25 8:03:00 AM ET
      $NRXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announce Signing of a Term Sheet for Strategic Investment from a Global Medical Device Manufacturer into HOPE

      Investment to support initiation of HOPE's network of clinics to treat suicidal depression and PTSD with ketamine, TMS and other modalities MIAMI, April 3, 2025 /PRNewswire/ -- HOPE Therapeutics, Inc., ("HOPE," the "Company"), an interventional psychiatry network wholly owned by NRx Pharmaceuticals, Inc. ("NRx") (NASDAQ:NRXP), today announced signing of a term sheet with a global medical device manufacturer, as anticipated in the Company's recently filed annual report. The investor shares HOPE's vision of providing comprehensive interventional psychiatry treatments to patients around the world. 

      4/3/25 8:03:00 AM ET
      $NRXP
      Biotechnology: Pharmaceutical Preparations
      Health Care